Hims & Hers Health (NYSE:HIMS) Shares Gap Up - Still a Buy?

Key Points

• Hims & Hers Health shares opened at $43.00, up from a previous close of $41.53, and last traded at $44.31 with a volume of over 3 million shares.
• Analysts have varied ratings on the stock, with a consensus price target of $38.92 and nine analysts giving a hold rating or lower, indicating caution among investors.
• The company reported Q2 earnings of $0.17 per share, missing estimates, while revenue grew by 72.6% year-over-year but also fell short of expectations.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report)'s stock price gapped up before the market opened on Wednesday . The stock had previously closed at $41.53, but opened at $43.00. Hims & Hers Health shares last traded at $44.31, with a volume of 3,033,395 shares trading hands.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on HIMS shares. Zacks Research cut Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 19th. Morgan Stanley reiterated an "equal weight" rating and set a $40.00 price objective on shares of Hims & Hers Health in a research note on Wednesday, June 11th. Citigroup reiterated a "sell" rating on shares of Hims & Hers Health in a research note on Monday, June 23rd. Truist Financial lowered their price objective on Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating for the company in a research note on Monday, August 18th. Finally, Wall Street Zen cut Hims & Hers Health from a "buy" rating to a "hold" rating in a research note on Monday, July 28th. Two equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Reduce" and an average target price of $38.92.

Hims & Hers Health Stock Performance

The company has a market cap of $10.94 billion, a PE ratio of 60.49, a PEG ratio of 3.25 and a beta of 2.14. The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 4.46. The business has a 50-day moving average of $50.03 and a 200 day moving average of $45.41.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). The firm had revenue of $544.83 million for the quarter, compared to analysts' expectations of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The firm's revenue was up 72.6% compared to the same quarter last year. During the same quarter last year, the company posted $0.06 EPS. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Andrew Dudum sold 128,127 shares of the stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $45.06, for a total transaction of $5,773,402.62. Following the completion of the sale, the chief executive officer owned 89,521 shares in the company, valued at approximately $4,033,816.26. This trade represents a 58.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Soleil Boughton sold 2,571 shares of the stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $44.53, for a total value of $114,486.63. Following the sale, the insider owned 150,450 shares of the company's stock, valued at $6,699,538.50. This represents a 1.68% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,390,328 shares of company stock valued at $71,468,298. 13.71% of the stock is currently owned by corporate insiders.

Institutional Trading of Hims & Hers Health

Institutional investors have recently made changes to their positions in the business. Virtus Advisers LLC purchased a new stake in shares of Hims & Hers Health during the second quarter worth about $26,000. Quaker Wealth Management LLC purchased a new stake in shares of Hims & Hers Health during the second quarter worth about $29,000. Bessemer Group Inc. grew its position in shares of Hims & Hers Health by 105.8% during the second quarter. Bessemer Group Inc. now owns 607 shares of the company's stock worth $30,000 after purchasing an additional 312 shares in the last quarter. Geneos Wealth Management Inc. bought a new position in Hims & Hers Health during the first quarter valued at approximately $30,000. Finally, Skandinaviska Enskilda Banken AB publ boosted its stake in Hims & Hers Health by 408.2% during the second quarter. Skandinaviska Enskilda Banken AB publ now owns 747 shares of the company's stock valued at $37,000 after buying an additional 600 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.